Q2 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by Zacks Research

Amarin Co. plc (NASDAQ:AMRN) – Research analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Amarin in a research report issued to clients and investors on Tuesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Amarin’s current full-year earnings is ($0.14) per share. Zacks Research also issued estimates for Amarin’s Q1 2026 earnings at ($0.05) EPS.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $56.52 million for the quarter, compared to the consensus estimate of $51.34 million. Amarin had a negative return on equity of 9.43% and a negative net margin of 18.96%. During the same period in the prior year, the business posted ($0.04) earnings per share.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $1.08.

Amarin Stock Up 0.5 %

AMRN stock traded up $0.00 during trading on Friday, hitting $0.92. The company had a trading volume of 216,992 shares, compared to its average volume of 1,920,864. The firm has a market capitalization of $378.97 million, a P/E ratio of -7.65 and a beta of 1.96. Amarin has a 52-week low of $0.65 and a 52-week high of $1.49. The company has a 50 day simple moving average of $0.95 and a 200-day simple moving average of $0.94.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. purchased a new stake in Amarin during the first quarter valued at approximately $37,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Amarin by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 34,725 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in Amarin by 100.6% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 23,313 shares during the last quarter. SVB Wealth LLC grew its stake in Amarin by 100.0% during the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 30,000 shares during the last quarter. Finally, Gilliland Jeter Wealth Management LLC acquired a new position in Amarin during the 4th quarter valued at about $64,000. Hedge funds and other institutional investors own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.